NCT02114333View on ClinicalTrials.gov

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2020

Conditions
ShinglesHerpes Zoster
Interventions
BIOLOGICAL

Zostavax

0.65ml, subcutaneous

BIOLOGICAL

HZ/su vaccine

0.5ml, intramuscular

BIOLOGICAL

Placebo

0.65ml, subcutaneous

Trial Locations (1)

80045

Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine, Aurora

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT02114333 - Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds | Biotech Hunter | Biotech Hunter